The contribution of proteomics to the identification of biomarkers for cutaneous malignant melanoma

Clinical Biochemistry

Volumn 46, Issue 6, 2013, Pages 518-523

  Bougnoux, A C ^a,b   Solassol, J ^a,b,c  

^a UNIV MONTPELLIER   (France)

^b CENTRE VAL D AURELLE   (France)

^c HÔPITAL ARNAUD DE VILLENEUVE   (France)

Author keywords

Markers; Melanoma; Proteomics

Indexed keywords

PROTEOME; TUMOR MARKER; DIAGNOSTIC AGENT; PLASMA PROTEIN;

CANCER CELL CULTURE; CANCER TISSUE; CELL CULTURE; CUTANEOUS MELANOMA; HUMAN; MELANOMA CELL; PRIORITY JOURNAL; PROTEOMICS; REVIEW; TISSUE MICROARRAY; VALIDATION STUDY; BLOOD; GENETICS; ISOLATION AND PURIFICATION; MASS SPECTROMETRY; MELANOMA; PROGNOSIS; SKIN TUMOR; DIAGNOSTIC USE; SKIN NEOPLASMS;

BLOOD PROTEINS; HUMANS; MELANOMA; PROGNOSIS; PROTEOMICS; SKIN NEOPLASMS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR MARKERS, BIOLOGICAL;

EID: 84891687430     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2012.12.011     Document Type: Review

References (37)

1. Balch C.M., Buzaid A.C., Soong S.J., Atkins M.B., Cascinelli N., Coit D.G., et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001, 19:3635-3648.
2. Aitchison T.C., Sirel J.M., Watt D.C., MacKie R.M. Prognostic trees to aid prognosis in patients with cutaneous malignant melanoma. Scottish Melanoma Group. BMJ 1995, 311:1536-1539. [discussion 1539-41].
3. Becker D., Mihm M.C., Hewitt S.M., Sondak V.K., Fountain J.W., Thurin M. Markers and tissue resources for melanoma: meeting report. Cancer Res 2006, 66:10652-10657.
4. Agarwala S.S., Keilholz U., Gilles E., Bedikian A.Y., Wu J., Kay R., et al. LDH correlation with survival in advanced melanoma from two large, randomised trials (Oblimersen GM301 and EORTC 18951). Eur J Cancer 2009, 45:1807-1814.
5. Eton O., Legha S.S., Moon T.E., Buzaid A.C., Papadopoulos N.E., Plager C., et al. Prognostic factors for survival of patients treated systemically for disseminated melanoma. J Clin Oncol 1998, 16:1103-1111.
6. Zimmer D.B., Cornwall E.H., Landar A., Song W. The S100 protein family: history, function, and expression. Brain Res Bull 1995, 37:417-429.
7. Martenson E.D., Hansson L.O., Nilsson B., von Schoultz E., Mansson Brahme E., Ringborg U., et al. Serum S-100b protein as a prognostic marker in malignant cutaneous melanoma. J Clin Oncol 2001, 19:824-831.
8. Hamberg A.P., Korse C.M., Bonfrer J.M., de Gast G.C. Serum S100B is suitable for prediction and monitoring of response to chemoimmunotherapy in metastatic malignant melanoma. Melanoma Res 2003, 13:45-49.
9. Smit L.H., Korse C.M., Hart A.A., Bonfrer J.M., Haanen J.B., Kerst J.M., et al. Normal values of serum S-100B predict prolonged survival for stage IV melanoma patients. Eur J Cancer 2005, 41:386-392.
10. Hauschild A., Engel G., Brenner W., Glaser R., Monig H., Henze E., et al. S100B protein detection in serum is a significant prognostic factor in metastatic melanoma. Oncology 1999, 56:338-344.
11. Egberts F., Hitschler W.N., Weichenthal M., Hauschild A. Prospective monitoring of adjuvant treatment in high-risk melanoma patients: lactate dehydrogenase and protein S-100B as indicators of relapse. Melanoma Res 2009, 19:31-35.
12. Hill B.R., Levi C. Elevation of a serum component in neoplastic disease. Cancer Res 1954, 14:513-515.
13. Balch C.M., Gershenwald J.E., Soong S.J., Thompson J.F., Atkins M.B., Byrd D.R., et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009, 27:6199-6206.
14. Fung E.T., Wright G.L., Dalmasso E.A. Proteomic strategies for biomarker identification: progress and challenges. Curr Opin Mol Ther 2000, 2:643-650.
15. Solassol J., Jacot W., Lhermitte L., Boulle N., Maudelonde T., Mange A. Clinical proteomics and mass spectrometry profiling for cancer detection. Expert Rev Proteomics 2006, 3:311-320.
16. Cazares L.H., Diaz J.I., Drake R.R., Semmes O.J. MALDI/SELDI protein profiling of serum for the identification of cancer biomarkers. Methods Mol Biol 2008, 428:125-140.
17. Mian S., Ugurel S., Parkinson E., Schlenzka I., Dryden I., Lancashire L., et al. Serum proteomic fingerprinting discriminates between clinical stages and predicts disease progression in melanoma patients. J Clin Oncol 2005, 23:5088-5093.
18. Wilson L.L., Tran L., Morton D.L., Hoon D.S. Detection of differentially expressed proteins in early-stage melanoma patients using SELDI-TOF mass spectrometry. Ann N Y Acad Sci 2004, 1022:317-322.
19. Findeisen P., Zapatka M., Peccerella T., Matzk H., Neumaier M., Schadendorf D., et al. Serum amyloid A as a prognostic marker in melanoma identified by proteomic profiling. J Clin Oncol 2009, 27:2199-2208.
20. Joos T.O., Schrenk M., Hopfl P., Kroger K., Chowdhury U., Stoll D., et al. A microarray enzyme-linked immunosorbent assay for autoimmune diagnostics. Electrophoresis 2000, 21:2641-2650.
21. Forgber M., Trefzer U., Sterry W., Walden P. Proteome serological determination of tumor-associated antigens in melanoma. PLoS One 2009, 4:e5199.
22. Suzuki A., Iizuka A., Komiyama M., Takikawa M., Kume A., Tai S., et al. Identification of melanoma antigens using a Serological Proteome Approach (SERPA). Cancer Genomics Proteomics 2010, 7:17-23.
23. Liu Y., He J., Xie X., Su G., Teitz-Tennenbaum S., Sabel M.S., et al. Serum autoantibody profiling using a natural glycoprotein microarray for the prognosis of early melanoma. J Proteome Res 2010, 9:6044-6051.
24. Tamburro D., Fredolini C., Espina V., Douglas T.A., Ranganathan A., Ilag L., et al. Multifunctional core-shell nanoparticles: discovery of previously invisible biomarkers. J Am Chem Soc 2011, 133:19178-19188.
25. Longo C., Gambara G., Espina V., Luchini A., Bishop B., Patanarut A.S., et al. A novel biomarker harvesting nanotechnology identifies Bak as a candidate melanoma biomarker in serum. Exp Dermatol 2011, 20:29-34.
26. Hanke S., Besir H., Oesterhelt D., Mann M. Absolute SILAC for accurate quantitation of proteins in complex mixtures down to the attomole level. J Proteome Res 2008, 7:1118-1130.
27. Colzani M., Schutz F., Potts A., Waridel P., Quadroni M. Relative protein quantification by isobaric SILAC with immonium ion splitting (ISIS). Mol Cell Proteomics 2008, 7:927-937.
28. Liu H., Ong S.E., Badu-Nkansah K., Schindler J., White F.M., Hynes R.O. CUB-domain-containing protein 1 (CDCP1) activates Src to promote melanoma metastasis. Proc Natl Acad Sci U S A 2011, 108:1379-1384.
29. Al-Ghoul M., Bruck T.B., Lauer-Fields J.L., Asirvatham V.S., Zapata C., Kerr R.G., et al. Comparative proteomic analysis of matched primary and metastatic melanoma cell lines. J Proteome Res 2008, 7:4107-4118.
30. Kim H., Kim W.J., Jeon S.T., Koh E.M., Cha H.S., Ahn K.S., et al. Cyclophilin A may contribute to the inflammatory processes in rheumatoid arthritis through induction of matrix degrading enzymes and inflammatory cytokines from macrophages. Clin Immunol 2005, 116:217-224.
31. Rondepierre F., Bouchon B., Papon J., Bonnet-Duquennoy M., Kintossou R., Moins N., et al. Proteomic studies of B16 lines: involvement of annexin A1 in melanoma dissemination. Biochim Biophys Acta 2009, 1794:61-69.
32. Bernard K., Litman E., Fitzpatrick J.L., Shellman Y.G., Argast G., Polvinen K., et al. Functional proteomic analysis of melanoma progression. Cancer Res 2003, 63:6716-6725.
33. Caputo E., Maiorana L., Vasta V., Pezzino F.M., Sunkara S., Wynne K., et al. Characterization of human melanoma cell lines and melanocytes by proteome analysis. Cell Cycle 2011, 10:2924-2936.
34. Paulitschke V., Kunstfeld R., Mohr T., Slany A., Micksche M., Drach J., et al. Entering a new era of rational biomarker discovery for early detection of melanoma metastases: secretome analysis of associated stroma cells. J Proteome Res 2009, 8:2501-2510.
35. Stromberg S., Agnarsdottir M., Magnusson K., Rexhepaj E., Bolander A., Lundberg E., et al. Selective expression of Syntaxin-7 protein in benign melanocytes and malignant melanoma. J Proteome Res 2009, 8:1639-1646.
36. Hardesty W.M., Kelley M.C., Mi D., Low R.L., Caprioli R.M. Protein signatures for survival and recurrence in metastatic melanoma. J Proteomics 2011, 74:1002-1014.
37. Liotta L.A., Petricoin E. Cancer biomarkers: closer to delivering on their promise. Cancer Cell 2011, 20:279-280.